20% off purchase of 3 or more products* | Learn More >>

Monoclonal Antibody Western Blotting Mitochondrial

Also showing Monoclonal Antibody Western Blotting Malate Dehydrogenase Decarboxylating Activity, Monoclonal Antibody Western Blotting Oxaloacetate Decarboxylase Activity, Monoclonal Antibody Malate Dehydrogenase Decarboxylating Activity

$122
20 µl
$293
100 µl
APPLICATIONS
REACTIVITY
Human, Monkey

Application Methods: Immunofluorescence (Immunocytochemistry), Immunohistochemistry (Paraffin), Western Blotting

Background: Malic enzymes catalyze oxidative decarboxylation of malate to pyruvate (1). The malic enzyme family in mammalian cells includes the cytosolic malic enzyme 1 (ME1) and two mitochondrial malic enzymes (ME2 and ME3) (1, 2). ME1 and ME2 are critical for tumor cell growth and their expression is repressed by tumor suppressor p53 (2). Reduced expression of ME1 and ME2 reciprocally increases the levels and activation of p53, promoting p53-mediated senescence (2). Research studies show ME3 is essential for the survival of pancreatic ductal adenocarcinoma following genomic deletion of ME2 (3). Deletion of ME3 is lethal to ME2-null cancer cells, which has been suggested to provide a potential therapeutic opportunity using collateral lethality (3, 4).

$293
100 µl
APPLICATIONS
REACTIVITY
Human, Monkey

Application Methods: Flow Cytometry, Immunofluorescence (Immunocytochemistry), Western Blotting

Background: Malic enzymes catalyze oxidative decarboxylation of malate to pyruvate (1). The malic enzyme family in mammalian cells includes the cytosolic malic enzyme 1 (ME1) and two mitochondrial malic enzymes (ME2 and ME3) (1, 2). ME1 and ME2 are critical for tumor cell growth and their expression is repressed by tumor suppressor p53 (2). Reduced expression of ME1 and ME2 reciprocally increases the levels and activation of p53, promoting p53-mediated senescence (2). Research studies show ME3 is essential for the survival of pancreatic ductal adenocarcinoma following genomic deletion of ME2 (3). Deletion of ME3 is lethal to ME2-null cancer cells, which has been suggested to provide a potential therapeutic opportunity using collateral lethality (3, 4).